Abstract
Sphingosine kinase 1 (SK1) catalyses the formation of bioactive phospholipid sphingosine 1-phosphate (S1P). Elevated cellular SK1 activity and S1P levels enhance cell proliferation and survival, and are strongly implicated in tumourigenesis. Regulation of SK1 activity can occur through various mechanisms, including phosphorylation and protein–protein interactions. We have previously shown that eukaryotic elongation factor 1A (eEF1A) interacts with and directly activates SK1, but the mechanisms regulating this were undefined. Notably, eEF1A has GTPase activity and can exist in GTP- or GDP-bound forms, which are associated with distinct structural conformations of the protein. Here, we show that the guanine nucleotide-bound state of eEF1A regulates its ability to activate SK1, with eEF1A.GDP, but not eEF1A.GTP, enhancing SK1 activity in vitro. Furthermore, we show that enhancing cellular eEF1A.GDP levels through expression of a guanine nucleotide dissociation inhibitor of eEF1A, translationally controlled tumour protein (TCTP), increased SK1 activity in cells. We also examined a truncated isoform of eEF1A1, termed prostate tumour inducer-1 (PTI-1), which can induce neoplastic cell transformation through undefined mechanisms. PTI-1 lacks the G protein domain of eEF1A1 and is therefore unable to undergo the GTP-binding-induced conformational change. Notably, we found that PTI-1 can directly activate SK1 and that this seems to be essential for neoplastic transformation induced by PTI-1, as chemical SK1 inhibitors or overexpression of a dominant-negative SK1 blocked this process. Thus, this study defines the mechanism regulating eEF1A-mediated SK1 activation, and also establishes SK1 as being integral for PTI-1-induced oncogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abbott CM, Proud CG . (2004). Translation factors: in sickness and in health. Trends Biochem Sci 26: 25–31.
Al-Maghrebi M, Anim JT, Olalu AA . (2005). Up-regulation of eukaryotic elongation factor-1 subunits in breast carcinoma. Anticancer Res 25: 2573–2577.
Andersen GR, Nissen P, Nyborg J . (2003). Elongation factors in protein biosynthesis. Trends Biochem Sci 28: 434–441.
Andersen GR, Pedersen L, Valente L, Chatterjee I, Kinzy TG, Kjeldgaard M et al. (2000). Structural basis for nucleotide exchange and competition with tRNA in the yeast elongation factor complex eEF1A:eEF1Bα. Mol Cell 6: 1261–1266.
Cans C, Passer BJ, Shalak V, Nancy-Portebois V, Crible V, Amzallag N et al. (2003). Translationally controlled tumor protein acts as a guanine nucleotide dissociation inhibitor on the translation elongation factor eEF1A. Proc Natl Acad Sci USA 100: 13892–13897.
Cuvillier O . (2008). Downregulating sphingosine kinase-1 for cancer therapy. Expert Opin Ther Targets 12: 1009–1020.
Ejiri S . (2002). Moonlighting functions of polypeptide elongation factor 1: from actin bundling to zinc finger protein R1-associated nuclear localization. Biosci Biotechnol Biochem 66: 1–21.
French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL et al. (2003). Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 63: 5962–5969.
Gopalkrishnan RV, Su Z-z, Goldstein NI, Fisher PB . (1999). Translational infidelity and human cancer: role of the PTI-1 oncogene. Int J Biochem Cell Biol 31: 151–162.
Hait NC, Oskeritzian CA, Paugh SW, Milstein S, Spiegel S . (2006). Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 1758: 2016–2026.
Kahns S, Lund A, Kristensen P, Knudsen CR, Clark BF, Cavallius J et al. (1998). The elongation factor 1 A-2 isoform from rabbit: cloning of the cDNA and characterization of the protein. Nucleic Acids Res 26: 1884–1890.
Kawamori T, Kaneshiro T, Okumura M, Maalouf S, Uflacker A, Bielawski J et al. (2009). Role for Sphingosine kinase 1 in colon carcinogenesis. FASEB J 23: 405–414.
Kohno M, Momoi M, Oo ML, Paik JH, Lee YM, Venkataraman K et al. (2006). Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol 26: 7211–7223.
Leclercq T, Morretti PA, Vadas M, Pitson SM . (2008). Eukaryotic elongation factor 1A interacts with sphingosine kinase and directly enhances its catalytic activity. J Biol Chem 283: 9606–9614.
Lee JM . (2003). The role of protein elongation factor eEF1A2 in ovarian cancer. Reprod Biol Endocrinol 1: 69–73.
Liu H, Peng HW, Cheng YS, Yuan HS, Yang-Yen HF . (2005). Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP. Mol Cell Biol 25: 3117–3126.
Mansilla F, Friis I, Jadidi M, Nielsen KM, Clark BF, Knudsen CR . (2002). Mapping the human translation elongation factor eEF1H complex using the yeast two-hybrid system. Biochem J 365: 669–676.
Mansilla F, Hansen LL, Jakobsen H, Kjeldgaard NO, Clark BFC, Knudsen CR . (2005). Deconstructing PTI-1: PTI-1 is a truncated, but not mutated, from of translation elongation factor 1A1, eEF1A1. Biochim Biophys Acta 1727: 116–124.
Panasyuk G, Nemazanyy I, Filonenko V, Negrutskii B, El′skaya AV . (2008). A2 isoform of mammalian translation factor eEF1A displays increased tyrosine phosphorylation and ability to interact with different signalling molecules. Int J Biochem Cell Biol 40: 63–71.
Pitson SM, D′Andrea RJ, Vandeleur L, Moretti PA, Xia P, Gamble JR et al. (2000). Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A dominant-negative sphingosine kinase. J Biol Chem 350: 429–441.
Pitson SM, Moretti PAB, Zebol JR, Lynn HE, Xia P, Vadas MA et al. (2003). Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J 22: 5491–5500.
Pitson SM, Moretti PAB, Zebol JR, Zareie R, Derian CK, Darrow AL et al. (2002). The nucleotide-binding site of human sphingosine kinase 1. J Biol Chem 277: 49545–49553.
Pitson SM, Xia P, Leclercq TM, Moretti PA, Zebol JR, Lynn HE et al. (2005). Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signaling. J Exp Med 201: 49–54.
Roberts JL, Moretti PA, Darrow AL, Derian CK, Vadas MA, Pitson SM . (2004). An assay for sphingosine kinase activity using biotinylated sphingosine and streptavidin-coated membranes. Anal Biochem 331: 122–129.
Satoh T, Endo M, Nakafuku M, Nakamura S, Kaziro Y . (1990). Platelet-derived growth factor stimulates formation of active p21ras.GTP complex in Swiss mouse 3T3 cells. Proc Natl Acad Sci USA 87: 5993–5997.
Soares DC, Barlow PN, Newbery HJ, Porteous DJ, Abbott CM . (2009). Structural models of human eEF1A1 and eEF1A2 reveal two distinct surface clusters of sequence variation and potential differences in phosphorylation. PLoS One 4: e6315.
Sprang SR . (1997). G protein mechanisms: insights from structural biology. Annu Rev Biochem 66: 639–678.
Su Z, Goldstein NI, Pisher PB . (1998). Antisense inhibition of the PTI-1 oncogene reverses cancer phenotypes. Proc Natl Acad Sci USA 95: 1764–1769.
Susini L, Besse S, Duflaut D, Lespagnol A, Beekman C, Fiucci G et al. (2008). TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ 15: 1211–1220.
Taha TA, Hannun YA, Obeid LM . (2006). Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 39: 113–131.
Thornton S, Anand N, Purcell D, Lee J . (2003). Not just for housekeeping: protein initiation and elongation factors in cell growth and tumourigenesis. J Mol Med 81: 536–548.
Tuynder M, Fiucci G, Prieur S, Lespagnol A, Géant A, Beaucourt S et al. (2004). Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci USA 101: 15364–15369.
Tuynder M, Susini L, Prieur S, Besse S, Fiucci G, Amson R et al. (2002). Biological models and genes of tumor reversion: Cellular reprogramming through tpt1/TCTP and SIAH-1. Proc Natl Acad Sci USA 99: 14976–14981.
Xia P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW et al. (2000). An oncogenic role of sphingosine kinase. Curr Biol 10: 1527–1530.
Yu L, Wu G, Wang L, Wang H, Zhang G . (2006). Transient reduction of PTI-1 expression by short interfering RNAs inhibits the growth of human prostate cancer cell lines. Tohoku J Exp Med 209: 141–148.
Acknowledgements
This work was supported by the Fay Fuller Foundation, an Australian Postgraduate Award (to TML), Project Grant 399330 from the Cancer Council of South Australia and a Senior Research Fellowship from the National Health and Medical Research Council of Australia (to SMP).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Leclercq, T., Moretti, P. & Pitson, S. Guanine nucleotides regulate sphingosine kinase 1 activation by eukaryotic elongation factor 1A and provide a mechanism for eEF1A-associated oncogenesis. Oncogene 30, 372–378 (2011). https://doi.org/10.1038/onc.2010.420
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2010.420
Keywords
This article is cited by
-
A novel 3’tRNA-derived fragment tRF-Val promotes proliferation and inhibits apoptosis by targeting EEF1A1 in gastric cancer
Cell Death & Disease (2022)
-
Overexpressing eukaryotic elongation factor 1 alpha (eEF1A) proteins to promote corticospinal axon repair after injury
Cell Death Discovery (2022)
-
EEF1D overexpression promotes osteosarcoma cell proliferation by facilitating Akt-mTOR and Akt-bad signaling
Journal of Experimental & Clinical Cancer Research (2018)
-
Binding of eEF1A2 to the RNA-dependent protein kinase PKR modulates its activity and promotes tumour cell survival
British Journal of Cancer (2018)
-
Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin
Scientific Reports (2016)